98%
921
2 minutes
20
Cardiovascular-kidney-metabolic (CKM) syndrome with high incidence and mortality rates is a prevalent health issue globally. The Metabolic Score for Visceral Fat (METS-VF), as a new index for valuating visceral adipose tissue, has been reported to be closely related to a variety of diseases. However, whether the METS-VF can be an indicator to predict the risk of CKM syndrome remains unclear. We selected National Health and Nutrition Examination Survey (NHANES) database data from the 2011-2020 year cycles and conducted analyses between the METS-VF and CKM syndrome utilizing weighted Cox regression models, subgroup and interaction analysis, and restricted cubic spline (RCS) analysis. We also used receiver operating characteristic (ROC) curves to analyze and compare the diagnostic predictive ability of the METS-VF, the BMI, and other indicators assessing adipose tissue, including the VAI, fat mass, and lean mass, in CKM syndrome. In this study, the average age was 34.40 ± 0.61 years in the non-CKM patients, while the average age was over 40.38 ± 0.62 years in the CKM patients. Additionally, there was a greater proportion of male patients in the CKM patients (over 49.04%) in comparison with the non-CKM patients (37.94%). The average METS-VF was higher in the CKM patients (over 6.63 ± 0.02) compared with the non-CKM patients (5.62 ± 0.03). We found the METS-VF had a positive correlation with CKM syndrome and was hardly affected by other confounding factors. The METS-VF was more closely associated with CKM syndrome in the subgroup of age 20-59 and female patients. In addition, the METS-VF had better diagnostic ability for CKM syndrome than the body mass index (BMI) and other indicators. The METS-VF is a potentially actionable indicator that had a positive correlation with CKM risk. The METS-VF may be used as a possible reference in the management of CKM syndrome.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11988761 | PMC |
http://dx.doi.org/10.3390/healthcare13070694 | DOI Listing |
Mol Cell Biochem
September 2025
Peking University Third Hospital, Beijing, China.
Cardiovascular-Kidney-Metabolic (CKM) syndrome, a newly defined systemic disorder, is characterized by the pathological interplay among diabetes, chronic kidney disease (CKD), and cardiovascular disease (CVD). Recent studies have identified chronic inflammation not only as a central mediator in the pathological progression of CKM syndrome but also as a pivotal molecular hub that drives coordinated damage across multiple organ systems. Mechanistic investigations have revealed that aberrant activation of signaling pathways such as NF-κB, Wnt, PI3K-AKT, JAK-STAT, and PPAR constitutes a complex inflammatory regulatory network.
View Article and Find Full Text PDFThe relationship between gut microbiota, diet, and cardiovascular-kidney-metabolic (CKM) health has attracted attention. However, the relationship between the dietary index for gut microbiota (DI-GM) and CKM syndrome has not yet been studied. Patients diagnosed with CKM syndrome from the NHANES 2007-2018 data were included.
View Article and Find Full Text PDFDev Dyn
September 2025
Department of Internal Medicine, Division of Cardiovascular Medicine, Francois M. Abboud Cardiovascular Research Center, Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, Iowa, USA.
Background: Gene transcription is crucial for embryo and postnatal development and is regulated by the Mediator complex. Mediator is comprised of four submodules, including the kinase submodule (CKM). The CKM consists of MED13, MED12, CDK8, and CCNC.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
September 2025
Xiangya School of Medicine, Central South University, Changsha, China.
Background: The association of the triglyceride glucose (TyG) index and related TyG metrics with obesity indices has been demonstrated to correlate with the incidence of cardiovascular disease (CVD). Nonetheless, this relationship has not been thoroughly investigated in patients with cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3.
Methods: This study involved 7364 participants from the China Health and Retirement Longitudinal Study (CHARLS).
Heart Lung Circ
September 2025
Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA,
Cardiovascular-kidney-metabolic (CKM) syndrome is a term that is increasingly used to describe interconnected conditions that lead to poor health outcomes, including cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. Historically, there have been very few targeted pharmacotherapies available that have changed cardiovascular outcomes for people with CKM syndromes; however, over the past decade, new pharmacologic options have rapidly expanded, with strong evidence for cardiovascular and kidney protective benefits in CKM conditions. Of note, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have emerged as key therapeutic options and are now widely guideline-endorsed.
View Article and Find Full Text PDF